An experimental coronavirus treatment pill is making headlines on Friday (October 1). The oral drug, called molnupiravir, is being developed by Merck & Co Inc.
and Ridgeback Biotherapeutics LP, and reduced hospitalization and death by around 50% according to clinical trial results, via Reuters. Click inside to read more… The companies plan to seek U.S.
emergency use authorization for the pill as soon as possible, as well as worldwide. If it is authorized, it will be the first oral antiviral medication for COVID-19. “This is going to change the dialogue around how to manage COVID-19,” said Merck’s Robert Davis to Reuters.